-
3
-
-
33847607537
-
The burden of allergic rhinitis
-
Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007; 28:3-9.
-
(2007)
Allergy Asthma Proc
, vol.28
, pp. 3-9
-
-
Nathan, R.A.1
-
4
-
-
78650918994
-
Allergen immunotherapy: a practice parameter third update
-
Cox L, Nelson H, Lockey R et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1-55.
-
(2011)
J Allergy Clin Immunol
, vol.127
-
-
Cox, L.1
Nelson, H.2
Lockey, R.3
-
5
-
-
80051734103
-
Mechanisms of immunotherapy to aeroallergens
-
Shamji MH, Durham SR. Mechanisms of immunotherapy to aeroallergens. Clin Exp Allergy 2011; 41:1235-46.
-
(2011)
Clin Exp Allergy
, vol.41
, pp. 1235-1246
-
-
Shamji, M.H.1
Durham, S.R.2
-
6
-
-
78650898599
-
Disease-modifying effect and economic implications of sublingual immunotherapy
-
Canonica GW, Passalacqua G. Disease-modifying effect and economic implications of sublingual immunotherapy. J Allergy Clin Immunol 2011; 127:44-5.
-
(2011)
J Allergy Clin Immunol
, vol.127
, pp. 44-45
-
-
Canonica, G.W.1
Passalacqua, G.2
-
8
-
-
75849127328
-
Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009
-
Canonica GW, Bousquet J, Casale T et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64(Suppl 91):1-59.
-
(2009)
Allergy
, vol.64
, Issue.SUPPL. 91
, pp. 1-59
-
-
Canonica, G.W.1
Bousquet, J.2
Casale, T.3
-
9
-
-
36248986032
-
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis
-
Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338-45.
-
(2007)
J Allergy Clin Immunol
, vol.120
, pp. 1338-1345
-
-
Didier, A.1
Malling, H.J.2
Worm, M.3
-
10
-
-
58149109018
-
Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis
-
Wahn U, Tabar A, Kuna P et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123(160-66):e3.
-
(2009)
J Allergy Clin Immunol
, vol.123
, Issue.160-166
-
-
Wahn, U.1
Tabar, A.2
Kuna, P.3
-
11
-
-
80052259321
-
Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis
-
Didier A, Worm M, Horak F et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011; 128:559-66.
-
(2011)
J Allergy Clin Immunol
, vol.128
, pp. 559-566
-
-
Didier, A.1
Worm, M.2
Horak, F.3
-
12
-
-
79955375673
-
The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials
-
Grouin JM, Vicaut E, Jean-Alphonse S et al. The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials. Clin Exp Allergy 2011; 41:1282-8.
-
(2011)
Clin Exp Allergy
, vol.41
, pp. 1282-1288
-
-
Grouin, J.M.1
Vicaut, E.2
Jean-Alphonse, S.3
-
13
-
-
0032845559
-
Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire
-
Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 1999; 104:364-9.
-
(1999)
J Allergy Clin Immunol
, vol.104
, pp. 364-369
-
-
Juniper, E.F.1
Thompson, A.K.2
Ferrie, P.J.3
Roberts, J.N.4
-
14
-
-
84876708386
-
-
Committee for Medicinal Products for Human Use. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006. London: European Medicines Agency
-
Committee for Medicinal Products for Human Use. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006. London: European Medicines Agency, 2008.
-
(2008)
-
-
-
15
-
-
84870294264
-
Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE
-
e1
-
Cox LS, Casale TB, Nayak AS et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012; 130:1327-34. e1.
-
(2012)
J Allergy Clin Immunol
, vol.130
, pp. 1327-1334
-
-
Cox, L.S.1
Casale, T.B.2
Nayak, A.S.3
-
16
-
-
84887023687
-
Efficacy and safety of 2-month pre-seasonal and co-seasonal treatment with a 5-grass pollen allergen extract sublingual tablet
-
Zeldin RK, Rodriguez P, Abiteboul K, Montagut A, de Blay F. Efficacy and safety of 2-month pre-seasonal and co-seasonal treatment with a 5-grass pollen allergen extract sublingual tablet. Allergy Asthma Proc 2013.
-
(2013)
Allergy Asthma Proc
-
-
Zeldin, R.K.1
Rodriguez, P.2
Abiteboul, K.3
Montagut, A.4
de Blay, F.5
-
17
-
-
0033549827
-
Long-term clinical efficacy of grass-pollen immunotherapy
-
Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75.
-
(1999)
N Engl J Med
, vol.341
, pp. 468-475
-
-
Durham, S.R.1
Walker, S.M.2
Varga, E.M.3
-
18
-
-
33644900473
-
Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood
-
Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006; 61:198-201.
-
(2006)
Allergy
, vol.61
, pp. 198-201
-
-
Eng, P.A.1
Borer-Reinhold, M.2
Heijnen, I.A.3
Gnehm, H.P.4
-
19
-
-
0036217348
-
Long-term efficacy of preseasonal grass pollen immunotherapy in children
-
Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002; 57:306-12.
-
(2002)
Allergy
, vol.57
, pp. 306-312
-
-
Eng, P.A.1
Reinhold, M.2
Gnehm, H.P.3
-
20
-
-
34447132918
-
Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study
-
Jacobsen L, Niggemann B, Dreborg S et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943-8.
-
(2007)
Allergy
, vol.62
, pp. 943-948
-
-
Jacobsen, L.1
Niggemann, B.2
Dreborg, S.3
-
21
-
-
39149127957
-
Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years
-
e2.
-
Dahl R, Kapp A, Colombo G et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121:512-18, e2.
-
(2008)
J Allergy Clin Immunol
, vol.121
, pp. 512-518
-
-
Dahl, R.1
Kapp, A.2
Colombo, G.3
-
22
-
-
33746691245
-
Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis
-
Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:434-40.
-
(2006)
J Allergy Clin Immunol
, vol.118
, pp. 434-440
-
-
Dahl, R.1
Kapp, A.2
Colombo, G.3
-
23
-
-
73149111527
-
Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet
-
Durham SR, Emminger W, Kapp A et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125:131-8.
-
(2010)
J Allergy Clin Immunol
, vol.125
, pp. 131-138
-
-
Durham, S.R.1
Emminger, W.2
Kapp, A.3
-
24
-
-
84857797855
-
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial
-
Durham SR, Emminger W, Kapp A et al. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129:717-25.
-
(2012)
J Allergy Clin Immunol
, vol.129
, pp. 717-725
-
-
Durham, S.R.1
Emminger, W.2
Kapp, A.3
|